바이러스 벡터 및 플라스미드 DNA 제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 23.91 Billion in 2034 from USD 6.97 Billion in 2025, growing at a CAGR of 14.68% during 2026-2034.The Global Viral Vector & Plasmid DNA Manufacturing Market has witnessed rapid expansion driven by the growing adoption of gene therapies, cell therapies, and advanced biologics. Viral vectors such as lentivirus and adenovirus are essential for delivering genetic material in gene editing and immunotherapy applications. The surge in clinical trials for CAR-T therapies and rare disease treatments has significantly increased demand for high-quality vector and plasmid DNA production capabilities.

Key growth drivers include rising investment in biotechnology research, increasing regulatory approvals for gene-based therapies, and expanding partnerships between biotech firms and contract development and manufacturing organizations (CDMOs). Technological advancements in scalable manufacturing platforms and improved purification techniques have enhanced production efficiency. Governments and private investors are also funding infrastructure development to address supply constraints and accelerate commercialization.

Looking ahead, the market is poised for strong growth as gene therapy pipelines continue to expand globally. The transition from small-scale clinical manufacturing to large-scale commercial production will create significant opportunities. Innovations in suspension cell culture systems, automation, and closed manufacturing processes are expected to improve yields and reduce costs, supporting long-term expansion of the viral vector and plasmid DNA manufacturing industry.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Vector Type

• Adenovirus
• Retrovirus
• Adeno-Associated Virus (AAV)
• Lentivirus
• Plasmids
• Others

By Workflow

• Upstream Manufacturing
• Downstream Manufacturing

By Application

• Antisense & RNAi Therapy
• Gene Therapy
• Cell Therapy
• Vaccinology
• Research Applications

By End-use

• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes

By Disease

• Cancer
• Genetic Disorders
• Infectious Diseases
• Others

COMPANIES PROFILED

• Thermo Fisher Scientific, Merck KGaA, Lonza, Fujifilm Diosynth Biotechnologies, Catalent Inc., Wuxi Biologics, Cobra Biologics, Takara Bio Inc., BioMarin Pharmaceutical, RegenxBio, Inc., Miltenyi Biotec GmbH, Sirion Biotech GmbH, Batavia Biosciences, Waisman Biomanufacturing, Genezen Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY VECTOR TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Vector Type
• 4.2. Adenovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Retrovirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Adeno-Associated Virus (AAV) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Lentivirus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Plasmids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Workflow
• 5.2. Upstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Downstream Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Antisense & RNAi Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Vaccinology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Research Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical and Biopharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY DISEASE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Disease
• 8.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Genetic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Vector Type
  • 9.2.2 By Workflow
  • 9.2.3 By Application
  • 9.2.4 By End-use
  • 9.2.5 By Disease
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Vector Type
  • 9.3.2 By Workflow
  • 9.3.3 By Application
  • 9.3.4 By End-use
  • 9.3.5 By Disease
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Vector Type
  • 9.4.2 By Workflow
  • 9.4.3 By Application
  • 9.4.4 By End-use
  • 9.4.5 By Disease
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Vector Type
  • 9.5.2 By Workflow
  • 9.5.3 By Application
  • 9.5.4 By End-use
  • 9.5.5 By Disease
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Vector Type
  • 9.6.2 By Workflow
  • 9.6.3 By Application
  • 9.6.4 By End-use
  • 9.6.5 By Disease
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL VIRAL VECTOR & PLASMID DNA MANUFACTURING INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Thermo Fisher Scientific
  • 11.2.2 Merck KGaA
  • 11.2.3 Lonza
  • 11.2.4 Fujifilm Diosynth Biotechnologies
  • 11.2.5 Catalent Inc
  • 11.2.6 Wuxi Biologics
  • 11.2.7 Cobra Biologics
  • 11.2.8 Takara Bio Inc
  • 11.2.9 BioMarin Pharmaceutical
  • 11.2.10 RegenxBioInc
  • 11.2.11 Miltenyi Biotec GmbH
  • 11.2.12 Sirion Biotech GmbH
  • 11.2.13 Batavia Biosciences
  • 11.2.14 Waisman Biomanufacturing
  • 11.2.15 Genezen Laboratories